Company · founded 1991

Incyte (United States)

Wilmington, United States · incyte.com

Manage this page

Citations, last 5 years: 6 154
Works, last 5 years: 821
h-index: 265
Scientists listed: 0
Grants since 2016: 24

Grants received

2024–2027 · grant · PRMRP

Optimized Lyophilization and Reconstitution of ErythroMer, a Bio-Inspired, Artificial Red Blood Cell

William Mcghee · Incyte (United States) · funded by Congressionally Directed Medical Research Programs

$2.5M

2024–2025 · research · R41

NanoLuciferase-based AD/ADRD Microphysiological Systems Platform for High-throughput Screening

Wayne W Poon · Incyte (United States) · funded by National Institutes of Health

$500k

2023–2025 · cooperative agreement · Cooperative Agreement

SBIR Phase II: Wireless-Wireline Convergence

Akula Reddy · Incyte (United States) · funded by National Science Foundation

$1.2M

2023–2024 · contract · N43

A MINIATURIZED AD MPS PLATFORM FOR HIGH-THROUGHPUT DRUG SCREENING

Wayne Poon · Incyte (United States) · funded by National Institutes of Health

$500k

2023–2026 · cooperative agreement · Cooperative Agreement

SBIR Phase II: A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development

Konstantinos Tsioris · Incyte (United States) · funded by National Science Foundation

$1.2M

2023–2024 · research · R41

Miniaturized AD/ADRD Microphysiological Systems Platform for High-throughput Screening

Wayne W Poon · Incyte (United States) · funded by National Institutes of Health

$500k3D Printing in Biomedical Research

2022–2023 · grant · Standard Grant

SBIR Phase I: Wireless-Wireline Convergence

Akula Reddy · Incyte (United States) · funded by National Science Foundation

$250.1k

2022 · grant · Standard Grant

SBIR Phase I: Automated Processes for Rapid Analyzation of Biopsy Samples

Timothy Keller · Incyte (United States) · funded by National Science Foundation

$256k

2021–2025 · cooperative agreement · Cooperative Agreement

SBIR Phase II: Identification of disease resistance traits to improve the productivity and sustainability of soybean cultivation

Alex Schultink · Incyte (United States) · funded by National Science Foundation

$991.9k

2021–2023 · research · R43

Development of Immunostimulatory Virotherapy Without Neurotoxicity for the Treatment of Brain Malignancies

Matthew Stremlau · Incyte (United States) · funded by National Institutes of Health

$399.3kVirus-based gene therapy research

2021–2023 · research · R44

A proprietary single-cell analytics platform for accelerating biologics manufacturing

Ayca Yalcin Ozkumur · Incyte (United States) · funded by National Institutes of Health

$855.3k

2021–2024 · research · R44

A proprietary single-cell analytics platform for accelerating biologics manufacturing

Ayca Yalcin Ozkumur · Incyte (United States) · funded by National Institutes of Health

$855.3k

2020–2021 · grant · Standard Grant

SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response

Konstantinos Tsioris · Incyte (United States) · funded by National Science Foundation

$256k

2019–2020 · grant · Standard Grant

SBIR Phase I: Identification of disease resistance traits to improve the productivity and sustainability of soybean cultivation

Alex Schultink · Incyte (United States) · funded by National Science Foundation

$225kYeasts and Rust Fungi Studies

2018–2020 · research · R41

Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence

Eric Kaldjian · Incyte (United States) · funded by National Institutes of Health

$223.8k

2017–2020 · research · R44

Path to Commercialization of the first “off the shelf” T cell product

Adrian Philip Gee · Incyte (United States) · funded by National Institutes of Health

$986.8kPolyomavirus and related diseases

2017–2020 · research · R42

ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

Jennifer P. Richards · Incyte (United States) · funded by National Institutes of Health

$833.7kHemoglobin structure and function

2017–2021 · research · R42

ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

Nivesh Kumar Mittal · Incyte (United States) · funded by National Institutes of Health

$788.5kHemoglobin structure and function

2017–2021 · research · R44

Path to Commercialization of the first “off the shelf” T cell product

Adrian Philip Gee · Incyte (United States) · funded by National Institutes of Health

$1MPolyomavirus and related diseases

2017–2020 · research · R44

Path to Commercialization of the first “off the shelf” T cell product

Adrian Philip Gee · Incyte (United States) · funded by National Institutes of Health

$988.7kPolyomavirus and related diseases

2017–2027 · research · R44

ErythroMer: Nanoscale BioSynthetic Red Cell Substitute

Esma Alp · Incyte (United States) · funded by National Institutes of Health

$995.5k

2016–2017 · research · R43

Development of a Universal Influenza Vaccine Produced by Cell-Free Protein Synthesis

Jeff C Fairman · Incyte (United States) · funded by National Institutes of Health

$196.1kInfluenza Virus Research Studies

2016–2020 · research · R01

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

Sunitha Kakarla · Incyte (United States) · funded by U.S. Food and Drug Administration

$249.9k

2016–2018 · research · R01

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

Sunitha Kakarla · Incyte (United States) · funded by U.S. Food and Drug Administration

$66.6k